Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 7/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LGMN | Q99538 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | S100B | P04271 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13362039 | 0.91 | DPP4 (0.50) | GAKDPP4SUV39H2ALDH1A1TDP1 | |
| SCHEMBL5392814 | 0.91 | DPP4 (0.50) | GAKDPP4SUV39H2ALDH1A1TDP1 | |
| SCHEMBL17265199 | 0.89 | ALDH1A1 (0.46) | DPP4ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL29989539 | 0.88 | MEN1 (0.45) | DPP4ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL15358736 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL310068 | 0.86 | NTSR1 (0.43) | DPP4SUV39H2ALDH1A1TDP1CYP3A4 | |
| SCHEMBL3345453 | 0.86 | NTSR1 (0.43) | DPP4SUV39H2ALDH1A1TDP1CYP3A4 | |
| SCHEMBL30682434 | 0.86 | NTSR1 (0.43) | DPP4SUV39H2ALDH1A1TDP1CYP3A4 | |
| SCHEMBL1911855 | 0.84 | DPP4 (0.53) | DPP4SUV39H2ALDH1A1MAPTLMNA | |
| SCHEMBL13380460 | 0.84 | SUV39H2 (0.44) | DPP4SUV39H2ALDH1A1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| WO-2017097113-A1 | AMINOPYRIMIDINE COMPOUNDS FOR INHIBITING ACITIVITY OF PROTEIN TYROSINE KINASE | 深圳市塔吉瑞生物医药有限公司 | 2017-06-15 | — | — | WO | disclosed |
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | GAK 132/4885DPP4 2538/4885SUV39H2 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.